How Is Zoetis’ Stock Performance Compared to Other Pet Care Stocks?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Source: NASDAQ.COM
Company Overview and Stock Performance: Zoetis Inc., a leading producer of animal health products, has seen its stock decline 16.5% from its 52-week high, with a notable drop of 8.9% over the past year despite better-than-expected financial results for Q4 and fiscal 2024.
Future Outlook and Analyst Sentiment: Although Zoetis expects stagnant revenue growth for fiscal 2025, analysts maintain a "Strong Buy" rating on the stock, with a price target suggesting a potential 25.4% increase from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 79.330
Low
130.00
Averages
154.20
High
200.00
Current: 79.330
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition, misleading investors about its business prospects, which could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix's first-quarter margins were significantly boosted by advanced memory component purchases, yet the company failed to inform investors about dwindling supplies, leading to negative margin pressures that may affect future financial performance.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis did not disclose that its veterinary prescription growth was sharply declining due to FDA safety warnings, potentially weakening investor confidence in its market position.
- Lucid Group Lawsuit: Lucid Group faced significant delivery disruptions due to supplier quality issues in early 2026, failing to disclose this to investors, which could have a material negative impact on the company's financial results.
See More
Zoetis Executives Face Personal Liability Lawsuit Over Misleading Statements
- Executive Liability Lawsuit: Zoetis CEO Kristin Peck and CFO Wetteny Joseph face personal liability for allegedly certifying misleading statements, with the lawsuit claiming they failed to ensure the accuracy of the company's SEC filings from January 14, 2025, to May 6, 2026, potentially leading to individual criminal and civil penalties.
- Stock Price Plunge: Following a series of corrective disclosures, Zoetis shares fell 21.5% to close at $87.31 on May 7, 2026, indicating severe market concerns regarding the company's governance and transparency, which could undermine investor confidence and future financing capabilities.
- Competitive Pressure: The lawsuit highlights that Peck and Joseph did not disclose that Librela's adoption weakened due to FDA safety warnings and that Simparica Trio lost market share to lower-priced competitors, potentially jeopardizing the company's position in the highly competitive pet pharmaceuticals market.
- Legal Consequences: Under the Sarbanes-Oxley Act, both executives are held accountable for Zoetis's financial disclosures, and if found liable for intentional or negligent misstatements, they could face severe legal repercussions, further impacting the company's reputation and financial stability.
See More
Reminder of Zoetis Securities Fraud Class Action Lawsuit
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Zoetis Inc. that the deadline to join the securities fraud class action lawsuit is July 27, 2026, urging prompt submission of claims to participate in the litigation.
- Lawsuit Background: The lawsuit involves investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company and certain senior officers made materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: As a result of these alleged misrepresentations, Zoetis securities traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, indicating potential legal and financial risks for the company.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has successfully litigated hundreds of class actions, demonstrating its strong reputation and capability in protecting investor rights.
See More
Zoetis Securities Class Action Notice
- Class Action Initiated: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Declining Market Share: The lawsuit claims that veterinarian prescription growth and adoption of Zoetis' flagship product Librela have sharply weakened due to FDA safety warnings regarding serious neurological complications in dogs, leading to significant investor losses.
- Increased Competitive Pressure: Zoetis' Simparica Trio is losing substantial market share to a lower-priced competing canine parasiticide with broader indicated use, reflecting a slowdown in the overall market that further impacts the company's performance.
- Product Market Challenges: Zoetis' dermatology products, Apoquel and Cytopoint, are also facing significant market share losses due to newly launched competing treatments, indicating a weakening competitive position in its core product lines.
See More
Zoetis Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could adversely affect the company's reputation and stock price.
- Flat Earnings Report: In its Q1 2026 earnings, Zoetis reported net income of $601 million, unchanged year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, down from $7.00 to $7.10, reflecting a more challenging operating environment.
- Stock Price Plunge: Following the earnings release, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31 per share, highlighting market concerns regarding the company's future profitability and potentially diminishing investor confidence.
- Market Sensitivity: CEO Kristin Peck noted increased price sensitivity among pet owners, leading to a decline in veterinary visits and softer demand, a trend that could further impact Zoetis's market share and long-term growth prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Calix, Inc. Lawsuit: During the class period from January 28 to April 21, 2026, Calix is accused of failing to disclose that its first-quarter margins benefited from advanced purchasing of memory components, misleading investors about the company's prospects, which could negatively impact stock performance.
- AeroVironment, Inc. Lawsuit: From June 25, 2025, to March 10, 2026, AeroVironment allegedly understated imminent competition threats, leading to an overestimation of its business prospects, which may adversely affect investor confidence.
- Zoetis Inc. Lawsuit: Between January 14 and May 6, 2026, Zoetis is accused of not disclosing a slowdown in veterinarian prescription growth and market share losses, potentially leading investors to misjudge the company's future profitability, impacting stock prices.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced allegations of supply quality issues disrupting deliveries, failing to accurately disclose enhancements in manufacturing capabilities, which could mislead investors about the company's operations and affect market confidence.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition, misleading investors about its business prospects, which could negatively impact stock prices and investor confidence.
- Calix Lawsuit: Calix's first-quarter margins were significantly boosted by advanced memory component purchases, yet the company failed to inform investors about dwindling supplies, leading to negative margin pressures that may affect future financial performance.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis did not disclose that its veterinary prescription growth was sharply declining due to FDA safety warnings, potentially weakening investor confidence in its market position.
- Lucid Group Lawsuit: Lucid Group faced significant delivery disruptions due to supplier quality issues in early 2026, failing to disclose this to investors, which could have a material negative impact on the company's financial results.
See More
Zoetis Executives Face Personal Liability Lawsuit Over Misleading Statements
- Executive Liability Lawsuit: Zoetis CEO Kristin Peck and CFO Wetteny Joseph face personal liability for allegedly certifying misleading statements, with the lawsuit claiming they failed to ensure the accuracy of the company's SEC filings from January 14, 2025, to May 6, 2026, potentially leading to individual criminal and civil penalties.
- Stock Price Plunge: Following a series of corrective disclosures, Zoetis shares fell 21.5% to close at $87.31 on May 7, 2026, indicating severe market concerns regarding the company's governance and transparency, which could undermine investor confidence and future financing capabilities.
- Competitive Pressure: The lawsuit highlights that Peck and Joseph did not disclose that Librela's adoption weakened due to FDA safety warnings and that Simparica Trio lost market share to lower-priced competitors, potentially jeopardizing the company's position in the highly competitive pet pharmaceuticals market.
- Legal Consequences: Under the Sarbanes-Oxley Act, both executives are held accountable for Zoetis's financial disclosures, and if found liable for intentional or negligent misstatements, they could face severe legal repercussions, further impacting the company's reputation and financial stability.
See More
Reminder of Zoetis Securities Fraud Class Action Lawsuit
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Zoetis Inc. that the deadline to join the securities fraud class action lawsuit is July 27, 2026, urging prompt submission of claims to participate in the litigation.
- Lawsuit Background: The lawsuit involves investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026, alleging that the company and certain senior officers made materially false and misleading statements regarding business operations, growth prospects, and financial stability.
- Investor Losses: As a result of these alleged misrepresentations, Zoetis securities traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, indicating potential legal and financial risks for the company.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has successfully litigated hundreds of class actions, demonstrating its strong reputation and capability in protecting investor rights.
See More
Zoetis Securities Class Action Notice
- Class Action Initiated: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Declining Market Share: The lawsuit claims that veterinarian prescription growth and adoption of Zoetis' flagship product Librela have sharply weakened due to FDA safety warnings regarding serious neurological complications in dogs, leading to significant investor losses.
- Increased Competitive Pressure: Zoetis' Simparica Trio is losing substantial market share to a lower-priced competing canine parasiticide with broader indicated use, reflecting a slowdown in the overall market that further impacts the company's performance.
- Product Market Challenges: Zoetis' dermatology products, Apoquel and Cytopoint, are also facing significant market share losses due to newly launched competing treatments, indicating a weakening competitive position in its core product lines.
See More
Zoetis Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Zoetis, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could adversely affect the company's reputation and stock price.
- Flat Earnings Report: In its Q1 2026 earnings, Zoetis reported net income of $601 million, unchanged year-over-year, while cutting its full-year profit guidance to between $6.85 and $7.00 per share, down from $7.00 to $7.10, reflecting a more challenging operating environment.
- Stock Price Plunge: Following the earnings release, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31 per share, highlighting market concerns regarding the company's future profitability and potentially diminishing investor confidence.
- Market Sensitivity: CEO Kristin Peck noted increased price sensitivity among pet owners, leading to a decline in veterinary visits and softer demand, a trend that could further impact Zoetis's market share and long-term growth prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Calix, Inc. Lawsuit: During the class period from January 28 to April 21, 2026, Calix is accused of failing to disclose that its first-quarter margins benefited from advanced purchasing of memory components, misleading investors about the company's prospects, which could negatively impact stock performance.
- AeroVironment, Inc. Lawsuit: From June 25, 2025, to March 10, 2026, AeroVironment allegedly understated imminent competition threats, leading to an overestimation of its business prospects, which may adversely affect investor confidence.
- Zoetis Inc. Lawsuit: Between January 14 and May 6, 2026, Zoetis is accused of not disclosing a slowdown in veterinarian prescription growth and market share losses, potentially leading investors to misjudge the company's future profitability, impacting stock prices.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced allegations of supply quality issues disrupting deliveries, failing to accurately disclose enhancements in manufacturing capabilities, which could mislead investors about the company's operations and affect market confidence.
See More
